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The extraordinary plasticity of glioma cells allows them to contribute to different cellular 
compartments in the tumor vessels, reinforcing the vascular architecture. Recently, it was 
revealed that targeting glioma-derived pericytes, which represent a big percentage of the mural 
cell population in aggressive tumors, increases the permeability of the vessels and improves 
chemotherapy efficiency. However, the molecular determinants of this transdifferentiation 
process have not been elucidated. Here, we show that mutations in EGFR (epidermal growth 
factor receptor) stimulate the capacity of glioma cells to function as pericytes in a BMX (bone 
marrow and X-linked)/SOX9 dependent manner. The subsequent activation of PDGFR 
(platelet derived growth factor receptor beta) in the vessel walls of EGFR mutant gliomas 
stabilize the vasculature and facilitates the recruitment of immune cells. These changes in the 
tumor microenvironment confer a growth advantage to the tumors, although it also makes them 
particularly sensitive to pericyte-targeting molecules such as ibrutinib or sunitinib. In the 
absence of EGFR mutations, high-grade gliomas are enriched in blood vessels too but they 
show a highly disrupted blood-brain-barrier due to the decreased BMX/SOX9 activation and 
pericyte coverage, which lead to poor oxygenation, necrosis and hypoxia. Here, we identify 
EGFR mutations as key regulators of the glioma-to-pericyte transdifferentiation, highlighting 
the intricate relation between the tumor cells and their vascular and immune microenvironment. 
Our results lay the foundations for a vascular dependent stratification of gliomas and suggest 
different therapeutic vulnerabilities depending on the genetic status of EGFR, which defines 
the vascular and the immune landscape of the tumors. 
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Diffuse gliomas are histologically classified as low and intermediate-grade gliomas 
(Lower-Grade Gliomas, LGG) (grades two and three) or glioblastomas (GBMs) (grade four) 
[1]. The poor prognosis of these tumors has been attributed in part to treatment limitations 
related to the tumor localization, but also to the insufficient knowledge about their physiology.  
Florid vascular proliferation and aberrant vasculature are distinctive pathological 
hallmarks of glioma progression. Four distinct mechanisms of vascularization have been 
proposed in gliomas: vascular co-option, angiogenesis, vasculogenesis and vascular mimicry. 
The last one is associated with the plasticity of GBM cells, which can transdifferentiate into 
endothelial cells (ECs) [2] and pericytes [3, 4]. All these mechanisms are inter-linked and 
overlapped in the history of gliomas and give rise to an abnormal vascular network, with dilated 
and tortuous blood vessels (BVs) and poor pericyte coverage, which contributes to the 
formation of an abnormal blood-brain-barrier (BBB) [5].  
Whereas the mechanisms that drive glioma neo-vascularization have been described, 
the genetic alterations that govern them have not been well established. However, it is known 
that mutations in the isocitrate dehydrogenase 1/2 (IDH1/2) genes, commonly found in LGG, 
favor the normalization of the vasculature. IDH mutant (IDHmut) gliomas have smaller BVs 
and are associated with less hypoxia compared with their wild-type (wt) counterparts [6]. 
Moreover, we have recently described that the microtubule stabilizer TAU/MAPT is induced 
in IDHmut gliomas and promotes vascular normalization by opposing EGFR signaling [7]. The 
EGFR gene is amplified in 50 to 60% of IDHwt GBMs and half of these tumors carry the vIII 
variant (exons 2-7 deletion), which generates a constitutive activation of the receptor´s tyrosine 
kinase. In addition, missense point mutations in the extracellular domain of the receptor are also 
commonly found in gliomas [8]. All these mutations confer a higher oncogenic potential to the 
tumor cells through the increase in their proliferative capacity. Moreover, EGFR activation in 
glioma cells promotes STAT3/5 activation and cytokine secretion to modify the 
microenvironment and thus drives tumorigenesis [9]. This adds to the idea that the genotype of 
glioma driving cells determines their surrounding stroma. Here, we investigated how alterations 
in EGFR affect the vascular phenotype of gliomas and the implications for the progression of 
the tumors. Our results show the relevance of the glioma-to-pericyte transdifferentiation, driven 
by EGFR mutations in shaping the vascular and the immune phenotype of the tumors. The data 
highlight the intricate relation between the glioma cells and their surrounding stroma.  
 
Materials and Methods 
Human samples 
Glioma tissues were obtained after patient´s written consent (according to the Declaration of 
Helsinki) and with the approval of the Ethical Committee at Hospital 12 de Octubre (Madrid, 
Spain) (CEI 14/023 and CEI 18/024). The primary cell lines (Table S1) belong to the Biobank 
of that Hospital. Fresh tissue samples were digested enzymatically using Accumax (Millipore) 
and were maintained in stem cell medium; Neurobasal (Invitrogen) supplemented with B27 
(1:50) (Invitrogen); GlutaMAX (1:100) (Invitrogen); penicillin-streptomycin (1:100) (Lonza); 
0.4% heparin (Sigma-Aldrich); and 40 ng/ml EGF and 20 ng/ml bFGF2 (Peprotech). 
Mouse cell lines 
Mouse SVZ cell lines were obtained by retroviral expression of EGFRwt or EGFRvIII in 
primary neural stem cell cultures obtained from the subventricular zone (SVZ) of p16/p19 ko 
mice as previously described [10] and they were grown in stem cell medium. After infection, 
the cells were injected into Nude mice. The tumors that grew were dissociated and the lines 
SVZ-EGFRwt/amp and SVZ-EGFRvIII were established. Both models express GFP and 
luciferase as a reporter. The GL261 murine glioma cells were maintained in DMEM plus 10% 
FBS, 2mM L-glutamine, 0.1% penicillin (100 U/ml) and streptomycin (100 μg/ml). 
DNA constructs and lentiviral/retroviral production 
Retroviral vectors used were pBabe-EGFRwt (#11011) and MSCV-XZ066-GFP-EGFRvIII 
(#20737). pLV-Hygro-Luciferase (VectorBuilder #VB150916-10098). Lentiviral vector to 
express shRNAs were: shCD248 (Sigma #SHCLNG-NM_020404: TRCN00000437821) and 
shSOX9 (Adgene #40644).  
In vitro treatments 
Cells were treated with ibrutinib (MedChemExpress, 31976) 5µM, DMSO (control), MG132 
(Millipore) 10µM, or different concentrations of dacomitinib (Pfizer, PF-299804).  
In vivo assays 
Animal experiments were reviewed and approved by the Research Ethics and Animal Welfare 
Committee at our institution (Instituto de Salud Carlos III, Madrid) (PROEX 244/14 and 02/16), 
in agreement with the European Union and national directives. Intracranial or subcutaneoous 
transplantations into Nude mice were establish as previously described [11]. Mice were treated 
with ibrutinib at 12 mg/kg/day through intraperitoneal injection (i.p.), sunitinib (Selleckchem, 
S1042) at 6mg/kg/day (i.p.), or dacomitinib (Pfizer, PF-299804) at 15mg/Kg/day (i.p.). For 
drug preparation ibrutinib was dissolved in 4% DMSO + 10% Hydroxypropyl-β-Cyclodextrin 
(HP-β-CD), sunitinib was dissolved in 4% DMSO + 10% Polysorbate and dacomitinib was 
dissolved in 20mM sodium lactate (pH=4) (1,5mg/ml). Control animals were treated with these 
solvents. For MRI analyses, animals were previously anesthetized using 2 % isofluorane 
(Isobavet, Schering-Plough) and they were IP injected with 0,1 mL of Gd-DOTA (Dotarem, 
Guerbet). Images were acquired on a 4,7 T Biospec BMT 47/40 spectrometer (Bruker), 
equipped with a 6 cm actively shielded gradient system, capable of 450 mT/m gradient strength 




SVZ-EGFRwt/amp and SVZ-EGFRvIII tumors were surgically excised from nude mice and 
the tissue was dissociated of enzymatic digestion at room temperature with Accumax by 30 
min. Samples then were filtered through 70 m strainers and collected in staining medium (PBS 
containing 2% BSA). Live tumors cells were discriminated from dead cells using propidium 
iodide and GFP+ cells were isolated with BD FACS Cell Sorter. Cells were collected into 2 ml 
staining medium and were recovered by centrifugation for further analysis.  
Chicken chorioallantoic membrane (CAM) assay 
For in vivo evaluation of the angiogenic inductive potential of SVZ derived conditioned media 
(CM), a CAM assay was performed as previously reported [12]. Photographs were taken with 
a digital camera HD IC80 (Leica, Heidelberg, Germany) and the number of vessels within a 6-
mm radius of the scaffold were counted to determine the angiogenic score, using ImageJ 
software (NIH, USA).  In each photograph, the diameter of 220 vessels was measured using 
ImageJ software (NIH, USA). 
Inmunofluorescent (IF) and Inmunohistochemical (IHC) staining and quantification 
IF and IHC staining was performed as previously described [7] using primary and secondary 
antibodies described in Table S2. For quantification, slides were scanned at 63X or 40X 
magnification. The number of BrdU-positive cells per field was counted with Fiji-ImageJ 
software and normalized with the total number of cells. To quantify the IgG extravasation Fiji-
ImageJ software was used. The signal from the endomucin channel was subtracted from the 
IgG channel. To quantify delocalized pericytes, the signal from the endomucin channel was 
subtracted from the αSMA channel. For the quantification of the vasculature, we counted the 
number of dilated vessels per field and CD34 staining with Fiji-ImageJ software. A similar 
approach was used to count the number of immune cells (CD45 or CD68 positive cells per 
field). Density measurements of blood vessel density, necrotic area and pericytes coverage, 
were performed with ImageJ software (http://rsb.info.nih.gov/ij). Furthermore, in case of the 
necrotic area we used a score to grade the intensity of the quantified necrosis. To calculate 
vasculature per random field areas was measured in the intratumoral regions of tumor sections. 
Flow cytometry analysis of human tumors 
Tumors suspensions were obtained after mechanical and enzymatic disaggregation (Accumax 
(Merck Millipore) (15 min, room temperature (RT) and filtered through 70μM nylon mesh cell 
strainer (Fisher Scientific). Erythrocytes were lysed with Quicklysis buffer (Cytognos) and cells 
were incubated with hFcR Blocking (Miltenyi), previous to antibody (Table S2) incubation (20 
min at 4°C in PBS 1% fetal bovine serum (FBS)). Viable cells were labelled with a Fixable 
Viability Stain (Becton Dickinson) (20 min, RT). The analysis was conducted in a Macsquant10 
flow Cytometry (Miltenyi). Lymphoid and myeloid subsets were defined as in  [13]. 
In sillico analysis 
The Cancer Genome Atlas (TCGA) GBM, LGG and GBM+LGG dataset was accessed via 
cBioPortal (https://www.cbioportal.org/), UCSC xena-browser (https://xenabrowser.net) and 
Gliovis (http://gliovis.bioinfo.cnio.es) for extraction of the data: overall survival, gene´s 
expression level and the distribution of the different genetic alterations.  Kaplan-Meier survival 
curves were done upon stratification based into low and high groups using expression values 
from each gene. Significance of differences in survival between groups was calculated using 
the log-rank test. For the functionality studies we have used “David Gene ontolog” analysis. 
First, we selected a cluster of 365 genes co-expressed with SOX9, using the highest value of the 
spearman´s correlations. Then, “David gene ontology” analysis associates the expression of this 
genes with the biological processes involved. The hypoxic-related genes signature included 
hypoxia and HIF1α pathways genes. Ivy Gap date set analysis 
(http://glioblastoma.alleninstitute.org/) was used to analyze gene signature enrichment between 
the different anatomic structures identified in the tumor.  
Statistical Analysis 
GraphPad Prism 5 software was used for data presentation and statistical analysis. For bar 
graphs, the level of significance was determined by a two-tailed un-paired Student´s t-test. The 
difference between experimental groups was assessed by Paired t-Test and one-way ANOVA. 
For Kaplan-Meier survival curves, the level of significance was determined by the two-tailed 
log-rank test.. P values < 0.05 were considered significant (*p < 0.05; **p < 0.01; *** p< 0.001; 
**** p< 0.0001; n.s., non-significant). All quantitative data presented are the mean ± SEM. 
Precise experimental details (number of animals or cells and experimental replicates) are 
provided in the figure legends.  
Data availability 
The authors confirm that the data supporting the findings of this study are available within the 
article and its Supplementary material. 
Additional methodological details are provided in the Supplementary Material.  
 
Results  
Stratification of gliomas by the genetic status of IDH and EGFR distinguishes between 
different vascular phenotypes 
We first validated that the transcription of three recognized angiogenic markers 
(VEGFA, ANGPT2 and IGFBP2) shows a strong inverse correlation with the survival of glioma 
patients (S1A-S1C Fig), even if we consider LGG (S1D-S1F Fig) and GBM (S1G-S1I Fig) 
separately. Moreover, the progressive increase in their expression paralleled the evolution of 
the glioma disease (S1J-S1L Fig). We then measured the frequency of mutations (S1M-S1O 
Fig) and copy number amplifications (CNA) (S1P-S1S Fig) in the groups with high or low 
quantities of the three genes. As expected, the frequency of IDH1 mutations was much higher 
in the gliomas that contain less angiogenic-related mRNAs. Among the rest of the genes 
analyzed, we found a consistent enrichment in mutations and CNA of EGFR and EGFR-related 
molecules, like ELDR (EGFR long non-coding downstream RNA) or EGFR-AS1, in the most 
angiogenic tumors. 
Tumors with alterations in IDH1/2 and EGFR account for almost 90% of all gliomas in the 
cancer genome atlas (TCGA) cohort, and they show a mutually exclusive pattern, with only a 
small percentage of IDHmut gliomas harboring EGFR gains (Fig 1A). In order to relate the 
vascular features with these genetic alterations in gliomas we classified our own cohort of 
patient’s samples in three groups, IDHmut gliomas, IDHwt gliomas without EGFR mutations 
(herein called EGFRwt/amp) and IDHwt/EGFRmut gliomas, and we measured the amount of 
the angiogenic-related mRNAs. As it has been previously described [14], the vasculature of 
IDHmut tumors was close to normal and there was no overexpression of any of the three 
angiogenic and vascular markers in these tumors compared to normal brain tissue (Fig 1B-1D). 
Among gliomas, we noticed that there was a gradual increase in the amount of the three mRNAs 
from the IDHmut to the IDHwt/EGFRmut gliomas, being the IDHwt/EGFRwt/amp group in 
the middle (Fig 1B-1D). This result was consistent with the in silico data (S2A-S2C Fig) and 
with the immunohistochemical (IHC) (Fig 1E) and the transcriptional (Fig 1F, 1G) (S2D and 
S2E Fig) analysis of CD34 (ECs) and SMA (pericytes), which showed a gradual increase in 
the three glioma subgroups. The parameters that changed the most were the vascular density 
(Fig 1H) and the number of dilated BVs (Fig 1I), typical of malignant gliomas [15].  
Our results suggest that the IDH-EGFR-based stratification of gliomas allows the 
distinction of three different vascular phenotypes, highlighting important differences between 
gliomas that overexpress wild-type or mutant EGFR, probably related to the increased 
phosphorylation of the receptor (S2F Fig), and the increase in the expression of several 
angiogenesis-related signatures (S2G-S2J Fig) observed in the second group. We narrowed 
down the set of differentially expressed vascular genes to define a “vascular signature” and we 
confirmed its higher expression in EGFRmut compared to EGFRamp glioma patients (Fig 1J). 
Notably, this vascular signature showed a strong correlation with the overall survival of glioma 
patients (Fig 1K).  
 
Fig 1. Stratification of gliomas by the genetic status of IDH-EGFR distinguishes between 
different vascular phenotypes. (A) Distribution of somatic nonsilent mutations in IDH1/2 and 
EGFR in a TCGA (LGG+GBM) cohort (n=663). (B-D) qRT-PCR analysis of VEGFA (B), 
ANGPT2 (C) and IGFBP2 (D) expression in gliomas (n=93) classified as IDHmut, 
IDHwt/EGFRwt/amp and IDHwt/EGFRmut. HPRT was used for normalization. (E) 
Representative pictures of IHC staining of CD34 (Top) and αSMA (Bottom) in three 
representative tumors. (F-G) qRT-PCR analysis of CD34 (F) and αSMA (G) expression in 
gliomas (n=93). HPRT was used for normalization. (H) Quantification of the vascular density 
in (E) (n=46). (I) Quantification of the dilated blood vessels (BVs) in (E) (n=46).  (J) RNAseq 
analysis of angiogenesis-related genes in a TCGA (LGG+GBM) cohort (n=319). (K) Kaplan-
Meier overall survival curves of patients from the TCGA (LGG+GBM) cohort (n=319), 
stratified into 3 groups based on the expression of the vascular signature.  *P ≤ 0.05; ****P ≤ 
0.0001. n.s. not significant. Scale bars: 100 m.  
 
EGFR wt/amp and EGFR vIII cells have different vascular capacities. 
The results presented so far suggest important differences in the vascular architecture of 
gliomas depending on the presence of EGFR mutations. To test the effect of wt or mut EGFR 
cells in the surrounding vessels, in the absence of any masking effect of concomitant mutations 
in other genes, we generated two mouse glioma models by transforming SVZ progenitors from 
p16/p19 ko mice with retrovirus carrying the wt or the vIII isoform of the receptor (S3A and 
S3B Fig). These cells grew in vitro (S3C Fig) and they were both very sensitive to dacomitinib 
(S3D Fig), an inhibitor of the receptor´s tyrosine kinase activity [11]. The two mouse cell lines 
formed subcutaneous tumors, although SVZ-EGFRvIII cells grew faster (S3E Fig). Moreover, 
they were both very sensitive to dacomitinib in vivo (S3F and S3G).  
Orthotopic implantation of the SVZ models generated gliomas with a high penetrance. 
Tumor burden was higher after the injection of vIII-expressing cells (Fig 3A), which correlates 
with the worse prognosis of EGFRmut gliomas in comparison with those harboring the wt 
receptor (amplified or not) (Fig 3B). The IHC and the immunofluorescent (IF) analysis of the 
tumors revealed a higher compact and proliferative growth after EGFRvIII expression (Fig 3C 
and 3D). The vascular density was not significantly different between the two models (Fig 3E 
and 3F) but we observed a strong increase in the size of the vessels in EGFRvIII gliomas (Fig 
3E and 3G). To obtain an independent confirmation of this observation, we used the CAM 
assay, which has been widely used to study angiogenesis [16]. Bio-cellulose scaffolds were 
embedded in VEGFA (as a control) or conditioned media (CM) from SVZ-EGFRwt/amp or 
SVZ-EGFRvIII cells, and they were layered on top of growing CAMs (S3H Fig). Although the 
CM from both type of cells demonstrated a pro-angiogeneic capacity (S3I Fig), the diameters 
of the vessels formed were larger in the presence of CM from SVZ-EGFRvIII cells compared 
to their wild-type counterparts (S3J Fig). Moreover, we observed that the vascular signature 
was strongly upregulated in SVZ-EGFRvIII compared to SVZ-EGFRwt/amp tumors (Fig 3H 
and 3I). Notably, some of the top genes in this comparative analysis were linked to pericytic 
differentiation (Cd248) and function (Timp1) (Fig 3I).  Overall, these results confirm the pro-
angiogenic function of EGFR signaling in gliomas. Moreover, they suggest that the expression 
of different isoforms of the receptor have a distinct effect on the vascular microenvironment.  
 
Fig 3. EGFR wt/amp and EGFR vIII cells have different vascular capacities. (A) Kaplan-
Meier overall survival curves of mice that were orthotopically injected with SVZ-EGFRwt/amp 
or SVZ-EGFRvIII cells (n=10). (B) Kaplan-Meier overall survival curves of patients from the 
TCGA cohort (GBM+LGG) separated based on the genetic status of EGFR (n=272). (C) 
Representative images of hematoxylin and eosin (H&E) (Top) and BrdU uptake (Bottom) in 
sections from SVZ tumors. (D) Quantification of the percentage of BrdU+ cells in SVZ tumors 
(n=3). (E) Representative images of the endomucin IHC staining of SVZ glioma sections. (F-
G) Quantification of the vascular density (F) and the number of dilated blood vessels (BVs) (G) 
in (E) (n=5). (H) qRT-PCR analysis of angiogenesis-related genes in SVZ-EGFRwt/amp and 
SVZ-EGFRvIII tumors. Actin was used for normalization (n=5). (I) Heat map of gene 
expression analysis in H. Red: highest expression. Blue: lowest expression. ** P ≤0.01; ****P 
≤0.0001; n.s. not significant; Scale bars: 25 m (C), 100 m (E).  
 
EGFRwt/amp expression is associated with a hypoxic phenotype. 
 To our surprise, the magnetic resonance imaging (MRI) analysis of the grafted mice 
revealed a cumulative increase in the contrast enhancement of SVZ-EGFRwt/amp compared to 
SVZ-EGFRvIII injected brains (Fig 4A and 4B). We also observed a stronger extravasation of 
Evans Blue (S4A Fig) and IgG (Fig 4C and 4D) in SVZ-EGFRwt/amp compared to mutant 
tumors. These observations suggest that the integrity of the BBB is severely compromised in 
the former. The disruption of the BBB has been associated with impaired blood perfusion and 
the formation of hypoxic regions in tumors [17]. Accordingly, HIF1α expression (Fig 4E) and 
the hypoxia-related signature (Fig 4F) were higher in SVZ-EGFRwt/amp compared to SVZ-
EGFRvIII tumors. This signature was defined using the IvyGAP (Ivy GBM Atlas Project) data-
set analysis (S4B Fig), selecting the most relevant genes included in hypoxia and HIF1α 
pathways signatures that were up-regulated in the perinecrotic and pseudopalisading-cell-
necrosis tumor zones (S4C Fig). Notably, this signature was increased in mesenchymal (MES), 
compared to classic (CL) or proneural (PN) gliomas (S4D Fig) [18]. MES gliomas are 
characterized by a high frequency of EGFR amplifications (but not mutations) and show a 
higher overall fraction of necrotic area and a stronger expression of hypoxia-regulated genes 
compared to the other subtypes [18, 19]. By contrast, tumors harboring EGFR mutations tend 
to accumulate in the CL subgroup, characterized by a highly proliferative phenotype [18, 20]. 
 
 
Fig 4. EGFRwt/amp expression is associated with a hypoxic phenotype. (A) Representative 
T1 contrast enhanced MRI scans of mouse brains containing SVZ tumors at different time 
points after gadolinium (Gd) injection. (B) Quantification of the Gd extravasation in (A) (n=3). 
NERt: normalized enhancement ratio. (C) Representative images of endomucin and IgG IF 
staining of sections from SVZ tumors. (D) Quantification of IgG extravasation on (C) (n=16). 
(E) WB analysis and quantification of HIF1α in SVZ tumors. Actin was used for normalization. 
(F) qRT-PCR analysis of hypoxic-related genes signature in SVZ tumors (n=5). Actin was used 
for normalization. (G-H) Representative images (G) and quantification (H) of endomucin and 
IgG IF staining of sections from PDXs (n=11). (I) qRT-PCR analysis of hypoxic-related genes 
signature in EGFRwt/amp (n=9) and EGFRmut (n=10) PDXs. HPRT was used for 
normalization (PDXs). (J) Representative images of endomucin and IgG IF staining of sections 
from human glioma samples. (K) Quantification of IgG extravasation on (J) (n=10). (L) qRT-
PCR analysis of CAIX expression in human glioma samples. HPRT was used for normalization 
(n=89). (M) Representative pictures of the hematoxylin and eosin (H&E) staining of different 
GBMs. Necrotic areas are highlighted with a red line and the necrotic area score is represented 
between brackets. The percentage of tumors (n=48) with different necrotic area scores is shown 
on the right. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; Scale bars: 50 m (C), 25 m (G, J), 100 m 
(M).  
 
We then performed an IF analysis in different orthotopic patient-derived-xenografts 
(PDXs) that express EGFRwt/amp or EGFRmut (deletions and/or point mutations). We 
observed the increase in the permeability of IgG in the prior compared to the latter (Fig 4G and 
4H). This effect was paralleled by an upregulation of the hypoxia-related signature in 
EGFRwt/amp PDXs (Fig 4I). Notably, the extravasation of IgG was also increased in 
EGFRwt/amp compared to EGFRmut patients´ tumors (Fig 4J-4K). Besides, we found a strong 
increase in the expression of Carbonic Anhydrase IX (CAIX), one of the main HIF1α targets, in 
IDHwt/EGFRwt/amp gliomas compared to tumors with IDH or EGFR mutations (Fig 4L). 
IDHmut tumors contain a more “normalized” vasculature without vessel leakage [7] and a 
reduced extent of necrosis [21]. The histological analysis of the tumor´s sections confirmed 
these observations (Fig 4M). Moreover, it showed an accumulation of necrotic areas in 
EGFRwt/amp compared to EGFRmut gliomas (Fig 4M). These results suggest that the 
angiogenic signals induced by amplification or overexpression of wt EGFR result in a dense 
vascular network, but with a severely compromised BBB, a different phenotype to the one 
observed in mutant EGFR tumors. This vascular fragility is associated with a less efficient 
fueling of tumor proliferation and with the appearance of areas of necrosis and hypoxia.   
 
Glioma-derived pericytes stabilize the vasculature in EGFRmut tumors. 
SVZ-EGFRvIII tumors showed a highly compact growth, whereas in SVZ-
EGFRwt/amp tumors cells appeared detached from each other and from the tumor vessels (Fig 
5A). It has been shown that pericytic functions can be performed by the highly plastic glioma 
stem cells, which acquire mesenchymal and mural cell features [3] in a process regulated by 
EGFR signaling [7]. In agreement with these notions, some tumor cells expressed αSMA in 
both SVZ glioma models (Fig 5B). Furthermore, pericyte-related markers were expressed in 
GFP+ cells, sorted out after tumor dissociation, independently of the genetic status of EGFR 
(Fig 5C). However, we noticed an increased transcription of αSma and Cd248 in SVZ-
EGFRvIII tumor cells, compared to their wild-type counterparts (Fig 5D). Notably, among the 
vascular signature, several pericyte-related genes were upregulated in cultured SVZ-EGFRvIII 
cells (S5A Fig), suggesting that they express these markers even in the absence of the 
microenvironment-derived signals, and that this process is exacerbated in the presence of the 
mutant isoforms of the receptor. In agreement with these results, there was a significant increase 
in the expression of human SMA and CD248 (Fig 5E) and in the ratio of tumor pericytes to 
mouse ECs (S5B Fig) in EGFRmut compared to EGFRwt/amp PDXs. By contrast, the 
transcription of host pericyte genes in all the PDX tested was similar to that of normal mouse 
brain (Fig 5E and S5B Fig). Notably, human endothelial transcripts (CD31, END) were not 
overexpressed in the PDXs, independently of the genetic status of EGFR (S5C Fig). These 
results suggest that in the presence of EGFR mutations glioma cells have a higher capacity to 
differentiate into pericytes but not to ECs. Indeed, we found that up to 80% of the SMA+ cells 
in a patient´s tumor express the vIII mutation (S5D Fig). Moreover, we found an increased 
pericyte coverage in mouse (Fig 5F) and human (Fig 5G) glioma transplants. By contrast, we 
noticed that the amount of delocalized pericytes (those that were not in close contact with ECs) 
was higher in wild-type compared to mutant EGFR tumors (S5E and S5F Fig). 
 
 
Fig 5. Glioma-derived pericytes stabilize the vasculature in EGFRmut tumors. (A-B) 
Representative pictures of GFP+ glioma cells and endomucin (A) or αSMA (B) IF staining of 
sections from SVZ tumors. (C) qRT-PCR analysis of pericytic-related genes in GFP+ sorted 
cells from SVZ tumors (n=4). Human cDNA was used as negative control. Actin was used for 
normalization. (D) Comparative analysis of expression of pericytic markers in tumors from (C). 
(E) qRT-PCR analysis of pericytic–related genes in EGFRwt/amp and EGFRmut PDXs (n=5). 
Human and mouse tissue were used as control. HPRT or Actin were used for normalization. (F-
G) Representative images of endomucin and αSMA IF staining of sections from SVZ gliomas 
(F) and PDXs (G). Arrows point towards examples of αSMA-positive cell that do not localize 
close to endomucin+ cells. Quantification of the pericyte coverage is shown on the right of the 
images (F, n=10). (G, n=8). (H) WB and quantification of EGFRvIII, SMA and CD248 in 
GBM1 and GBM2 (EGFRwt/amp), GBM1-EGFRvIII, and GBM3 (EGFRamp/mut) cells. 
GAPDH was used as loading control. (I) Kaplan-Meier overall survival curves of mice that 
were orthotopically injected with GBM1, GBM1-EGFRvIII-shcontrol and GBM1-EGFRvIII-
shCD248 (n=6). (J) qRT-PCR analysis of CD248 and αSMA in the tumors in (I). HPRT was 
used for normalization (n=3). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; n.s. not significant. Scale 
bars: 10m (A-B), 25m (F-G).  
 
To further study the transdifferentiation function of mutant EGFR, we introduced 
EGFRvIII in GBM1 cells (EGFRamp). We observed a strong increase in the amount of αSMA 
and CD248 protein in vitro, similar to the expression observed in GBM3 cells 
(EGFRamp/EGFRvIII) (Fig 5H). Overexpression of the mutant receptor increased the 
aggressiveness of the GBM1 tumors (Fig 5I) and induced a higher transcription of human-
specific pericyte genes (Fig 5J). Notably, downregulation of CD248, a master regulator of 
pericyte differentiation in malignant solid tumors [22, 23], decreased the aggressiveness of 
GBM1-EGFRvIII tumors (Fig 5I), with a concomitant decrease in the expression of other 
pericyte makers (Fig 5J). Taken together, these results confirm that EGFR mutations promote 
the growth of gliomas, at least in part through the increase in the plasticity of the tumor cells, 
which can work as pericytes and reinforce the stability of the vessels.   
 
 EGFR mutations modulate the vascular properties of glioma cells in a BMX and SOX9 
dependent way. 
EGFR signaling activates transcription factors that drive tumor growth. We performed 
an in-silico analysis in order to find those factors overexpressed in EGFRmut gliomas but with 
a similar expression in wild-type or amplified EGFR gliomas. The best hit was the Sex-
determining region Y (SRY)-box 9 (SOX9) gene (S6A Fig), which has been previously linked 
to EGFR [24, 25]. We found a strong upregulation of the SOX9 protein (Fig 6A) and mRNA 
(Fig 6B) in those PDXs harboring EGFR mutations. Similarly, SOX9 was accumulated in SVZ-
EGFRvIII allografts, but not in SVZ-EGFRwt/amp or in GL261 (commonly used mouse glioma 
model) tumors (S6B Fig). Furthermore, in the presence of a proteosomal inhibitor the amount 
of SOX9 was increased in EGFRwt/amp cells but did not change in EGFRmut cells (Fig 6C), 
suggesting the stabilization of the protein in the latter.  
SOX9 participates in a variety of functions during development, although it has also 
been implicated in the regulation of cancer stem cells [26]. Moreover, we found a positive 
association of SOX9 with angiogenic processes in gliomas (Fig 6D). Downregulation of this 
protein in GBM3 (EGFRamp/EGFRvIII) (Fig 6E and 6F) or in GBM1-EGFRvIII (S6C and 
S6D Fig) cells impaired their orthotopic growth.  Notably, the expression of CD248 and other 
pericyte-related genes was decreased in GBM3-shSOX9 compared to control tumors (Fig 6F 
and S6E Fig), suggesting that SOX9 mediates the induction of pericyte properties in EGFRmut 
tumors. In agreement with that, we found a positive correlation between the transcription of 
SOX9 and different pericytic-related genes in gliomas (S6F-S6I Fig). Notably, we observed a 
decrease in the pericyte coverage (Fig 6G), concomitant with the upregulation of the IgG 
extravasation (Fig 6H) and the hypoxia-related signature expression (Fig 6I) in SOX9 interfered 
tumors. These observations reinforce the idea that blockade of the transdifferentiation capacity 
of EGFRmut GBM cells favors the fragility of the tumor vessels and the subsequent induction 
of hypoxia, similar to what occurs in tumors over-expressing wild-type EGFR.  
 
Fig 6. EGFR mutations modulate the vascular properties of glioma cells in a BMX- and 
SOX9-dependent way. (A) WB analysis and quantification of SOX9 expression in PDXs. 
GAPDH was used for normalization. (B) qRT-PCR analysis of SOX9 expression in PDXs 
(n=9). HPRT expression was used for normalization. (C) WB analysis of SOX9 in 
EGFRwt/amp cell lines (GBM1 and SVZ) and EGFRvIII cell lines (GBM3 and SVZ) in the 
absence or in the presence of MG132 (MG) (10µm). (D) Gene Ontology Enrichment Analysis 
performed using David Bioinformatics Resources on the cluster of genes that are positively co-
expressed with SOX9 in the TCGA (LGG+GB) cohort. (E) Kaplan-Meier overall survival 
curves of mice that were orthotopically injected with GBM3-shcontrol or GBM3-shSOX9 cells 
(n=6). (F) WB analysis and quantification of SOX9, CD248, αSMA and TIMP1 in the tumors 
in (E) (n=3). Actin was used as loading control. (G) Representative images of endomucin and 
αSMA IF staining of tumors in (E). Quantification of the pericyte coverage is shown on the 
right (n=3). (H) Representative images of endomucin and IgG IF staining of sections from 
tumors in (E). Quantification of IgG extravasation is shown on the right (n=3). (I) qRT-PCR 
analysis of hypoxic-related genes in the tumors in (E) (n=3). HPRT was used for normalization 
(J) WB analysis and quantification of pEGFR, pBMX, SOX9, pAKT and total EGFR in growth 
factor-starved SVZ-EGFRvIII cells incubated with EGF (100ng/ml) for the times indicated, in 
the presence of DMSO or Ibrutinib (5µm). Actin was used for normalization. (K-L) Kaplan-
Meier overall survival curves of mice that were orthotopically injected with SVZ-EGFRvIII 
cells (K) and SVZ-EGFRwt (L) and subsequently treated with intraperitoneal injections of 
ibrutinib (12mg/kg/day) (n=6). 
 
A recent study has discovered that the bone marrow and X-linked (BMX) nonreceptor 
tyrosine kinase is highly expressed in glioma derived-pericytes but not in normal mural cells in 
the brain [27]. However, the upstream signals have not been described yet. In order to test if 
EGFR signaling could be connected to BMX activation in glioma cells, we performed an in 
vitro analysis in response to EGF. Stimulation with the ligand induced EGFR activation and 
signaling in SVZ-EGFRvIII (Fig 6J) and SVZ-EGFRwt/amp (S6J Fig) cells. However, it only 
stimulated BMX phosphorylation in the presence of the mutation (Fig 6J and S6J Fig). 
Moreover, we observed an accumulation of SOX9 protein at short times after EGF stimulation 
in EGFRvIII (Fig 6J) but not in EGFRwt/amp cells (S6J Fig). Ibrutinib, a dual BMX/BTK 
(Bruton's tyrosine kinase) inhibitor that impairs tumor-to-pericyte transdifferentiation [27], 
blocked BMX stimulation and SOX9 accumulation in response to EGF in SVZ-EGFRvIII cells 
(Fig 6J). EGFR and AKT phosphorylation were impaired in the presence of ibrutinib in both 
types of cells (Fig 6J and S6J Fig). However, ibrutinib impaired tumor growth of SVZ-
EGFRvIII cells (Fig 6K), but not their wild-type counterparts (Fig 6L). The reduced tumor 
burden was paralled by a reduced phosphorylation of EGFRvIII and BMX, as well as a 
reduction in the expression of SOX9 and pericyte markers in the treated tumors (S6K Fig). 
These results suggest that EGFRmut-BMX signaling induces the accumulation of SOX9 protein 
and the subsequent formation of tumor-derived-pericytes, increasing the aggressiveness of 
EGFRmut gliomas but rendering these tumors sensitive to ibrutinib.  
 
PDGFRβ activation in the pericytes of EGFR mutant gliomas is responsible for the entrance 
of immune cells into the tumors 
In order to further characterize the vascular phenotype of wild-type and mutant EGFR 
gliomas, we compared the expression of several important signaling pathways in angiogenic 
and vascular development in the SVZ models. We observed a strong increase in the levels of 
phospho-PDGFRβ (platelet derived growth factor receptor-β), with no differences in the 
amount of total PDGFRβ, phospho-AKT or β-catenin in the tumors expressing EGFRvIII (S7A 
Fig). This increase was detected as well in several EGFRmut PDXs (S7B Fig) and human 
tumors (Fig 7A) compared to the wild-type tumors. In both type of samples, we found a strong 
correlation between the phosphorylation of EGFR and PDGFRβ (Fig 7B and S7B Fig). 
Activation of the latter in response to the secretion of PDGF ligands by endothelial cells is 
crucial for the proper integration of pericytes in the vessel walls [28]. In agreement with that, 
we detected specific phospho-PDGFRβ labelling adjacent to the endothelium in several 
EGFRmut PDXs (S7C Fig). Notably, PDGFRβ activation was not observed in SVZ-EGFRvIII 
cells in vitro or in GL261 tumors (S7A Fig), which show many vascular abnormalities, even 
though they do not carry any EGFR alteration [5].  
 
Fig 7. PDGFRβ activation in the pericytes of EGFR mutant gliomas is responsible for the 
entrance of immune cells into the tumors (A) WB analysis and quantification of pEGFR, 
pPDGFRβ in human tumors. GAPDH was used for normalization. (B) Correlation between 
pEGFR and pPDGFRβ in (A). (C-E) Correlation between the percentage of leukocytes (C), 
myeloid cells (D) and lymphocytes (E) in dissociated human samples (flow cytometry analyses) 
and the levels of phospho-EGFR (WB analyses) in the same tumors. (F) Representative pictures 
of the IHC staining of CD45 (Top) and CD68 (Bottom) in samples from IDHmut, 
IDHwt/EGFRwt/amp and IDHwt/EGFRmut gliomas. (G-H) Quantification of the amount of 
CD45 (G) and CD68 (H) positive cells per field in the three groups of gliomas. (I-K) Percentage 
of leukocytes (I), myeloid cells (J) and lymphocytes (K) in the three groups of gliomas (L) 
Kaplan-Meier overall survival curves of mice that were orthotopically injected with SVZ-
EGFRvIII cells and subsequently treated with intraperitoneal injection of sunitinib 
(6mg/kg/day) (n=6). (M) Representative images of endomucin and IgG IF staining in sections 
from tumors in (L). Quantification of IgG extravasation is shown on the right (n=3). (N) 
Representative images of CD68 IF staining in sections from tumors in (L). Quantification is 
shown on the right (n=3). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; n.s. not significant. Scale bars: 
10 m (F), 25 m (M). 
 
The results presented so far indicates that the presence of EGFR mutations in gliomas 
lead to activation of PDGFRin the pericytes that cover the tumor vessels. Emerging evidence 
suggest that these mural cells are essential players in the regulation of blood cells extravasation 
[29]. Moreover, the activation of PDGFRin pericytes has been shown to promote a latent 
immunological phenotype, which results in the recruitment of large numbers of leukocytes into 
the brain [30].  In agreement with that, we found a strong positive correlation between the levels 
of phosphorylation of this receptor in human samples and the percentage of leukocytes (Fig 
7C), myeloid (Fig 7D) and lymphoid (Fig 7E) cells detected by flow cytometry after tumor 
dissociation. The presence of these cells in gliomas also correlated with the levels of phospho-
EGFR (S7D-S7F Fig). Altogether, these data suggest that tumors expressing EGFR mutations, 
through the modulation of the vessel wall, have a stronger immune infiltrate. Indeed, the IHC 
analysis showed a significant accumulation of CD45 (leukocytes) (Fig 7F and 7G) and CD68 
(myeloid cells) (Fig 7F and 7H) positive cells in IDHwt/EGFRmut tumors, compared to the 
other groups of gliomas. Besides, we detected increased amounts of leukocytes (Fig 7I), 
myeloid (Fig 7J) and lymphoid (Fig 7K) cells in these tumors when measured by flow 
cytometry.    
In order to confirm the relevance of PDGFR activation in EGFRmut gliomas we 
exposed SVZ-EGFRvIII tumors to sunitinib, which reduced the amount of phosphorylated 
receptor in the tumors (S7G Fig). The drug impaired glioma growth and increased the overall 
survival of the injected mice (Fig 7L). In agreement with our previous results, we measured a 
reduced number of dilated BVs in the sunitinib-treated tumors (S7H Fig), concomitant with an 
increased IgG extravasation (Fig 7M) and an upregulation of the hypoxia-related signature (S7J 
Fig). In addition, sunitinib reduced the presence of immune cells in EGFRvIII tumors (Fig 7N). 
Altogether, these results confirm that the activation of PDGFRβ, upon recruitment of the 
pericytes to the vessels, is important for the permanence and the fully functional differentiation 
of these cells, stabilizing the vasculature in EGFRmut gliomas. Moreover, the data highlights 
that tumor-derived-pericytes drives tumor growth through the regulation of both, the vascular 
and the immune compartments of gliomas. 
 
Discussion 
In agreement with other authors [9, 31, 32], we have stablished a positive correlation 
between the presence of EGFR genetic alterations and the expression of angiogenic molecules 
and the appearance of vascular abnormalities. However, our data suggest for the first time that 
wild-type or mutant EGFR induce the formation of two distinct vascular phenotypes, which in 
turn differ from the normalized vasculature of mutant IDH1/2 gliomas. The first one is 
characterized by the instability of the BBB and the induction of hypoxic signals and necrotic 
areas in the tumors, whereas the second phenotype, induced by EGFR mutations, contains more 
robust and enlarged tumor vessels that nurture a very compact and hyperproliferative tumor 
tissue. In agreement with this, the MRI analysis showed an accumulation of Gd over time in 
SVZ-EGFRwt/amp tumors. These results could seem contradictory with the literature as it has 
been suggested that EGFRvIII gliomas have a higher perfusion values in dynamic contrast-
enhanced (DCE)-MRI analyses in the patients [33], as well as in animals models [34] [31]. This 
measure is related to the degree of vessel permeability, but it is also influenced by the blood 
flow and the vessel area, which are enlarged in SVZ-EGFRvIII compared to SVZ-EGFRwt/amp 
tumors. Based on our data, EGFRwt/amp tumors would show more contrast enhancement at 
longer times after Gd injection, due to the presence of leakier tumor vessels. Although long 
MRI studies are non-viable in clinical practice, emerging evidence indicates that 
multiparametric analysis of DCE-MRI data could offer greater insight into the status of the 
tumor vasculature [35]. Using such an approach, no major differences were described in the Gd 
enhancement of EGFRvIII gliomas, which were otherwise characterized by increased cell 
density and blood flow, compared to other tumors [36]. A similar study has revealed the 
existence of two different subtypes of IDHwt GBMs: a glycolytic phenotype with predominant 
neovasculature and a necrotic/hypoxic dominated phenotype. However, no correlation was 
stablished with the genetic status of EGFR [37]. These kind of studies or other approaches to 
measure tumor vessel caliber and/or structure in gliomas [15] would certainly help to 
characterize the contribution of the two different vascular ecosystems in IDHwt GBMs and how 
they evolve in response to therapy. 
Pericytes play an essential role maintaining the structure and function of the vessel wall 
and the BBB. These mural cells were thought to originate from mesenchymal progenitors that 
are recruited from the bone-marrow in response to hypoxia [41, 42]. However, it has been 
recently shown that the majority of vascular pericytes in GBMs derive from tumor cells [3]. A 
similar epithelial-to-pericyte transition has been proposed in other cancers, promoting vascular 
integrity and tumor growth [43]. Nevertheless, to date it was unknown if different genetic 
alterations could modulate this transdiferentation process. Results from this study and our 
recently published data [7] suggest that it is governed by the EGFR/BMX signaling pathway. 
Moreover, we have shown here that tumor cells expressing mutant isoforms of EGFR have a 
higher capacity to differentiate into functional pericytes and overexpress molecules such as 
CXCR4, CX45 and TIMP1, which could be responsible for the improved pericyte recruitment 
toward endothelial cells and the increase pericyte coverage observed in EGFRmut gliomas. 
These signals confer a higher aggressiveness to the tumors. However, they also increase their 
sensitivity to molecules that target pericytic function, such as ibrutinib. This BMX inhibitor 
specifically affects tumor-derived pericytes [27] and cancer stem cells [44], preserving normal 
brain cells, which could limit the toxicity of the drug. Besides, this compound inhibits mutant 
EGFR activity in gliomas [45], as well as in other cancers [46]. Ibrutinib is being tested on 
unselected GBM patients in combination with radio- and chemo-therapy (NCT03535350). We 
propose that its activity could be higher in tumors harboring EGFR mutations so future 
retrospective studies should be carried on to validate this idea.  
Downstream of EGFRmut/BMX signaling, we have found an enrichment of SOX9 
expression and protein stability. The oncogenic function of SOX9 has been proposed in 
different cancers [26], including gliomas [47, 48], where it induces proliferation and cell 
survival, partly through BMI1 upregulation [49]. Our data indicate that SOX9 also regulates 
the vascular properties of gliomas by inducing the cellular plasticity of tumor cells, which could 
be linked to its well-known effects in cancer stem cells [26]. Notably, SOX9 has been linked to 
the upregulation of PDGFR expression during development [50], and regulates genes 
involved in the extracellular matrix such as collagen, aggrecan and Timp1, which are involved 
in the maintenance of the blood vessel structure [51]. In addition, BMI1 has been linked to the 
regulation of the epithelial-to-mesenchymal transition [52], allowing us to propose that SOX9, 
either acting directly or through the modulation of BMI1, may act as a master regulator of the 
vascularization processes in gliomas, especially for those tumors carrying EGFR mutations. 
Our results suggest that once attached to the endothelial cells, there is an activation of 
PDGFRβ in the glioma-derived pericytes. This is a key signal for their fully differentiation and 
integration into the vessels, and provides the proliferative and survival cues needed to maintain 
the vascular structure [28]. Our results confirm the higher functionality of these tumor vessels 
in EGFR mutant tumors, as they are able to support the proliferative capacity of glioma cells 
and favor the extravasation of blood cells into the tumor stroma. Although pericytes were 
classically associated with structural functions, an accumulating body of evidence suggests that 
these cells also display immune properties, including antigen presenting activities and 
expression of cytokines and adhesion molecules to control the immune cell trafficking across 
vessel walls [29, 53]. Particularly, activation of PDGFRin pericytes has been shown to 
promote a latent immunological phenotype, which results in the expression of recruitment 
molecules in the adjacent endothelium and the entrance of large numbers of blood cells into the 
brain [30].  These results are in agreement with recent reports that strongly suggest that changes 
in the tumor vasculature affect the degree of extravasation of immune cells, as well as their pro 
or anti-tumor profiles [54-56]. Moreover, increasing evidences support the synergism between 
anti-angiogenic and immune-therapies in other cancers [57], as well as in gliomas [58]. 
Although no breakthrough has been achieved using sunitinib in GBM patients [59], our results 
suggest that there could be a synergistic effect with immune modulators. Moreover, we propose 
that patients harboring EGFR mutations could have a differential sensitivity, not only to 
PDGFR inhibitors but also to strategies targeting the immune compartment.  
 
In the absence of EGFR mutations, we have found an induction of HIF1α protein and 
function. A direct transcriptional activation of HIF1α by EGFR has been proposed in lung 
cancer, especially in the presence of mutations [38], but little is known about this interaction in 
gliomas. Although we cannot discard a direct regulation of HIF1α expression by EGFR 
activation, we believe that this TF is induced and/or stabilized in the tumor context in response 
to the environmental conditions (such as acidosis or nutrients/oxygen deprivation) that occur 
after the disruption of the BBB in EGFRwt/amp gliomas. Notably, there seems to be a 
reciprocal relation as tumor hypoxia up-regulates EGFR expression in lung cancers [38], as 
well as in gliomas [39], promoting its activation in the absence of mutations. This could serve 
as a pro-survival signal for hypoxic cancer cells. Moreover, hypoxia has been proposed to 
induce resistance to EGFR inhibitors in different cancers [40], suggesting that combinatorial 
approaches targeting both pathways could be a promising strategy for EGFRwt/amp gliomas.  
In summary, we propose the existence of two distinct microenvironmental phenotypes 
in IDHwt GBM, orchestrated by the genetic status of EGFR and the downstream modulation 
of BMX-SOX9 activity, which induces the transdifferentiation of tumor cells into pericytes 
(Fig 8). This model could have diagnostic as well as great predictive value, as the different 
subtypes could have a distinct sensitivity to anti-angiogenic or immunomodulatory strategies. 
Moreover, the function of the tumor-derived-pericytes could limit the entrance of cytotoxic 
therapies through the BBB [27, 60]. Overall, our results place the angiogenic properties of 
gliomas at the top of the glioma hierarchy and suggest that future combinatorial therapeutic 
approaches should combine agents targeting the glioma vasculature with conventional 
therapies, molecularly-directed drugs or immunotherapies. Moreover, these strategies should 
be tailor-designed for each specific glioma subtype. 
  
Fig 8. Schematic view of the role of IDH and EGFR on the regulation of the vascular 
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Supplementary Fig. 1. Association between the levels of angiogenic molecules and the 
aggressiveness and the genetic alterations of gliomas. (A-C) Kaplan-Meier overall survival 
curves of patients from the TCGA-LGG cohort (n=507). Patients were stratified into two groups 
based on high and low VEGFA (A), ANGPT2 (B) or IGFBP2 (C) expression values. (D-F) 
Kaplan-Meier overall survival curves of patients from the TCGA-GBM cohort (n=525). 
Patients were stratified into two groups based on high and low VEGFA (D), ANGPT2 (E) or 
IGFBP2 (F) expression values. (G-I) Kaplan-Meier overall survival curves of patients (TCGA, 
LGG+GBM cohort) (n=663), stratified into two groups based on high and low VEGFA (G), 
ANGPT2 (H) or IGFBP2 (I) expression values. (J-L) Analysis of VEGFA (J), ANGPT2 (K) and 
IGFBP2 (L) expression by RNAseq in gliomas (TCGA, LGG+GBM cohort) (n=663), grouped 
according to the clinical evolution (grade) of the tumors. (M-S) Frequency of gene mutations 
(M-O) or copy number amplification (P-S) in gliomas with high or low level of expression of 





Supplementary Fig. 2. Analysis of EGFR-IDH alterations and vascular molecules in 
human samples. (A-E) Analysis of mRNA levels of VEGFA (A), ANGPT2 (B), IGFBP2 (C), 
CD34 (D) and  αSMA (E) (RNAseq) in gliomas from the TCGA (LGG+GBM) cohort (n= 661). 
Tumors were stratified in three groups: IDHmut, IDHwt/EGFRwt/amp and IDHwt/GFRmut. 
(F) Quantification of the WB analysis of pEGFR in patients stratified in two groups based on 
EGFR alterations (n=33).  (G) Summary of the expression of genes from each signature showed 
below (H-J). The table depicts the fold increase expression in EGFRmut compared to 
EGFRwt/amp tumors and the p value of the increment in the expression. (H-J) Levels of 
expression of different signatures: hallmark angiogenesis (H), mural brain cell (I) and 
angiogenic secretome (J), in wt/amp or mut EGFR gliomas from the TCGA (LGG+GBM) 
cohort (n=319). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 ****P ≤ 0.0001; n.s. not significant. 
 
 
Supplementary Fig. 3. Characterization of the murine glioma models: SVZ EGFR wt/amp 
and SVZ EGFR vIII. (A) Representative diagram of the generation of the SVZ-EGFRwt/amp 
and the SVZ-EGFRvIII murine glioma models. (B) WB analysis of total EGFR in SVZ cell 
lines. Actin expression was used for normalization. (C) Representative images of SVZ cell lines 
grown in vitro. (D) Viability (represented as percentage related to the control) of SVZ cell lines 
grown in vitro in the presence of different concentrations of dacomitinib. (E) SVZ-
EGFRwt/amp and SVZ-EGFRvIII were implanted subcutaneously in the nude mice and tumor 
growth was measured with a caliper. The graph represents the fold increase in tumor volume 
(n=3). (F-G) SVZ-EGFRwt/amp (F) and SVZ-EGFRvIII (G) cells were implanted 
subcutaneously in the nude mice. When tumors became visible, animals were treated with 
dacomitinib (15mg/Kg/day). The graphs represent the fold increase in tumor volume (n=5). (H) 
Representative images of blood vessel formation around the bio-cellulose scaffolds. Scaffolds 
were incubated with culture media, culture media with VEGF (as a positive control) and culture 
media with conditioned media (CM) from SVZ-EGFRwt/amp or SVZ-EGFRvIII cells. (I-J) 
Analysis of the number of vessels (I) and the vessel diameter (J) in each condition in (H). ****P 
≤ 0.0001, n.s. not significant. Scale bar: 100 m. 
  
 
Supplementary Fig. 4. Association of EGFR alterations with BBB leakage and definition 
of a hypoxia signature in gliomas. (A) Representative image of the whole brain of mice 
harboring SVZ-EGFRwt/amp or SVZ-EGFRvIII gliomas tumor showing Evans Blue 
extravasation. (B) Selection of the most relevant genes of the hypoxia and the HIF1α pathway 
signatures that were up-regulated in the perinecreotic and pseudopalisading cell necrosis zones. 
YvyGap (IVY Glioblastoma atlas project) data set analysis was used. (C) Levels of expression 
of the hypoxic-related signature in gliomas of the TCGA (GBM) cohorts depending on the 
different anatomical regions of the tumors. (D) Levels of expression of the hypoxic-related 
signature in gliomas of the TCGA (GBM) cohort according to the molecular subtype’s 
classification. PN: proneural, MES: mesenchymal, CL: classic.  **P ≤ 0.01; ***P ≤ 0.001: 
****P ≤ 0.0001 
 
 
Supplementary Fig. 5. Participation of EGFR mutations in the formation of glioma-
derived pericytes. (A) qRT-PCR analysis of angiogenesis-related genes in SVZ-EGFRwt/amp 
and SVZ-EGFRvIII cells. Actin was used for normalization (n=3).  (B) Ratio of the expression 
of pericyte (mouse and human) to endothelial (mouse) genes (qRT-PCR analysis) in PDXs 
models expressing wt/amp or mut EGFR (n=7). (C) qRT-PCR analysis of endothelial–related 
genes in EGFRwt/amp and EGFRmut tumor xenografts. Human or mouse tissue was used as 
control. HPRT or Actin was used for normalization (n=5). (D) Representative images of αSMA 
and EGFRvIII immunofluorescent (IF) staining of sections from a tumor sample expressing 
EGFRvIII. The graph on the right shows the quantification of the fraction of pericytes carrying 
the EGFRvIII genetic alteration per field (n=9). (E-F) Quantification of the number of 
delocalized pericytes delocated in SVZ (E) or PDX (F) tumor sections. *P ≤ 0.05; **P ≤ 0.01; 
***P ≤ 0.001; n.s. not significant. Scale bar: 10 m. 
  
 
Supplementary Fig. 6. Correlation of SOX9 expression with EGFR mutations in gliomas. 
(A) Analysis of the expression of different transcription factors (RNAseq) in gliomas from the 
TCGA GBM+LGG cohort, n=306, grouped according to the genetic status of EGFR. (B) WB 
analysis and quantification of EGFR and SOX9 in tumor tissue extracts from SVZ and GL261 
tumors. Extracts from SVZ cells were used as controls and loaded on the right. The expression 
of Actin was used for normalization (C) Kaplan-Meier overall survival curves of mice that were 
orthotopically injected with GBM1, GBM1-EGFRvIII and GBM1-EGFRvIII-shSOX9 (n=6). 
(D) WB analysis of SOX9 expression in tumor tissue extracts from (C). GAPDH expression 
was used for normalization (n=3). (E) qRT-PCR analysis of SOX9, CD248, αSMA, CXCR4, 
CX45 and TIMP1 in the tumors formed by GBM3-shControl or GBM3-shSOX9 cells. The 
expression of HPRT was used for normalization (n=3). (F-I) Analysis of CD248 (F), CX45 (G), 
CXCR4 (H) and TIMP1 (I) mRNA expression (RNAseq) in gliomas from the TCGA 
LGG+GBM cohort (n=702). Tumors were classified in two groups based on high or low SOX9 
expression values. (J) WB analysis and quantification of pEGFR, pBMX, SOX9, pAKT and 
total EGFR total in extracts from SVZ-EGFRwt/amp cells incubated with EGF (100ng/ml) for 
the times indicated, in the presence of DMSO or Ibrutinib (5µm). Actin was used as loading 
control. (K) WB analysis and quantification of pEGFR, pBMX, SOX9, CD248 and αSMA in 
the tumors in SVZ-EGFRvIII tumors treated with control or ibrutinib (12mg/kg/day) (n=6). 
GAPDH was used for normalization. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.  
 
Supplementary Fig. 7. PDGFRβ signaling is activated in the blood vessels of mutant 
EGFR gliomas and stabilized the vasculature. (A) WB analysis and quantification of EGFR, 
pEGFR, PDGFRβ, pPDGFRβ, pAKT, AKT and β-Catenin in SVZ and GL261 tumors. Extracts 
from SVZ cells were loaded on the right as controls. Actin was used for normalization. (B) WB 
analysis of EGFR, pEGFR, PDGFRβ, pPDGFRβ in PDXs. GAPDH was used for 
normalization. Correlation between pEGFR and pPDGFRβ in shown on the right. (C) 
Representative images of the IF analysis of αSMA, endomucin and pPDGFRβ in sections from 
mutant EGFR PDXs. (D-F) Correlation between the percentage of leukocytes (D), myeloid 
cells (E) and lymphocytes (F) in dissociated samples (flow cytometry analyses) and the levels 
of phospho-EGFR (WB analyses) in the same tumors. (G) WB analysis and quantification of 
pPDGFRβ in intracranial SVZ-EGFRvIII tumors treated with vehicle or sunitinib 
(6mg/kg/day). Actin was using for normalization. (H) Representative images of endomucin 
IHC staining in SVZ-EGFVRvIII tumors. Quantification of the number of dilated blood vessels 
(BVs) is shown on the right (n=3). (I) qRT-PCR analysis of hypoxic-related genes in the tumors 
in SVZ-EGFVRvIII tumors (n=3). Actin was used for normalization. n.s. not significant; *P ≤ 
0.05; **P ≤ 0.01. Scale bars: 10 m (C), 25 m (I). 
 
  
Supplementary Materials and Methods 
Lentiviral/retroviral production 
Lentiviral and retroviral particles were produced in 293T cells with packaging plasmid 
pCMVdR8.74 (Addgene #Plasmid 22036) and VSV-G envelope protein plasmid pMD2G 
(Addgene #Plasmid 12259) using Lipofectamine and Plus reagent (Invitrogen).   
In vitro assays 
For the time-course experiments, cells were starved for two hours in the presence of 5 µM 
ibrutinib or DMSO before adding 100 ng/µl of EGF. Cells were collected at 0, 10, 30 and 240 
min before being chilled on ice and pelleted for WB. For MG132 (Millipore) treatment, 10 µM 
MG132 was added to the cells and collected 3 h after. Pellets were obtained for WB analysis. 
To test the viability of SVZ cells, 10000 cells grown in a 96-well microplate were incubated in 
the presence of dacomitinib (Pfizer, PF-299804) or vehicle (DMSO) for three days and cell 
viability was assessed by a colorimetric assay using a WST-1 reagent (Roche) according to 
manufacturer´s instructions.   
Intracraneal tumor formation  
Intracraneal orthotopic xeno- and allo-grafts were performed using a Hamilton syringe to inject 
100.000-300.000 cells (resuspended in 2 μl of stem cell medium) into athymic Nude-Foxn1nu 
brains (Harlan Iberica). The injections were made into the striatum (coordinates: A–P, −0.5 
mm; M–L, +2 mm, D–V, −3 mm; related to Bregma) using a Stoelting Stereotaxic device. 
When applicable, tumor growth was monitored in an IVIS equipment (Perkin Elmer) after 
intraperitoneal injection of D-luciferin (75 mg/Kg) (PerkinElmer). The animals were sacrificed 
at the onset of symptoms.  
Heterotopic allografts   
SVZ-EGFRwt/amp and SVZ-EGFRvIII cells (1× 106) were resuspended in culture media and 
Matrigel (BD) (1:10) and then subcutaneously injected into nude mice. When tumors reached 
a visible size the tumor volume was measured with a caliper every 5 days. Tumor volume = 
1/2(length × width2).  
Mouse magnetic resonance imaging (MRI) and quantification 
Global shimming was first performed and three scout images in axial, sagittal, and coronal 
direction were acquired using a T1 weighted spin echo sequence with a repetition time of 2.1 s 
and an effective echo time of 62 ms. The field of view (FOV) was of 3.0x3.0 cm2, the thickness 
of the slices was 2.0 mm and the matrix size was 256x128, with a total acquisition time of 33 
s. Then respiratory-gated T1-weighted spin echo images in coronal orientation were acquired 
for the tumor visualization with the next parameters: TR/TE = 505/10 ms; FOV=2.56x2.56 cm2; 
slice thickness: 1.0 mm; number of slices: 9; number of signal averages = 4; matrix size: 
256x192. Data were zero filled to obtain images of 256x256 pixels. The MRI images obtained 
were analyzed with the ImageJ software. Images were acquired Pre-gadolinium injection and 
10-, 25-, 45-, 65-, 90- and 115-minutes Post-gadolinium injection. In vivo Pre- and Post- images 
were analyzed using ImageJ software (National Institutes of Health, Bethesda, Maryland). The 
intensity signal was measured in regions of interest, tumor region (It), contralateral region (Ic) 
and an area outside the mouse (Inoise). The Signal-to-noise ratio (SNR) of the region of interest 
were measured for each slice and time point and it is defined by SNR(t)=It/Inoise, for the tumor 
region, and SNR(c)=Ic/Inoise for the contralateral region. The normalized enhancement ratio 
(NER%) of the tumor region to the contralateral region was calculated as %𝑁𝐸𝑅𝑡 =
[{(𝑆𝑁𝑅𝑡/𝑆𝑁𝑅𝑐)𝑝𝑜𝑠𝑡 − (𝑆𝑁𝑅𝑡/𝑆𝑁𝑅𝑐)𝑝𝑟𝑒}/(𝑆𝑁𝑅𝑡/𝑆𝑁𝑅𝑐)𝑝𝑟𝑒] × 100. 
Determination of BBB integrity with Evans Blue extravasation 
For Evans blue infusion, 2ml/kg of Evans blue (E-2129, Sigma-Aldrich, MO) (2% dilution in 
PBS) was injected intravenously into the tail vein. After 30 min, the mice were deeply 
anesthetized with isoflurane and transcardially perfused in the heart beating through the left 
ventricle with 50 ml of ice-cold PB 0.1M followed by 50 ml of ice-cold 4% paraformaldehyde 
(PFA) in PB 0.1M. Brains were dissected afterwards. 
Chicken chorioallantoic membrane (CAM) assay 
For in vivo evaluation of the angiogenic inductive potential of SVZ derived CM, a CAM assay 
was performed as previously reported (Casas et al., 2018). Briefly, fertilized chicken eggs 
(Agricola Chorombo, Chile) were incubated at 38.5 °C with constant humidity. At embryonic 
day 1 (E1), 3 mL of albumin was extracted from each egg; a round window (2 cm2) was created 
on E4. A Bio-cellulose scaffold of 6mm of diameter was filled with 100 µl of medium to be 
assed: CM from SVZ-EGFRwt/amp or SVZ-EGFRvII, culture media (as negative control) and 
100 µg VEGFA (positive control). On E8, the CAM vasculature was photographed; 
subsequently, each experimental condition scaffold was placed on top of the CAM; for each 
condition 14 eggs from different batches were used. On day E12, white cream was injected 
under the CAM before photographing every egg, in order to improve the visualization of the 
vessels.  
Inmunofluorescent (IF) and Inmunohistochemical (IHC) staining 
For immunostaining analyses, intracraneal tumors as well as human samples were fixed with 
4% PFA for 12h at 4ªC and then tumors were embedded in paraffin. Paraffin sections (5 μM) 
were obtained with a microtome. Some animals were injected intraperitoneally with BrdU 
(Sigma Aldrich) (50mg/Kg) in saline solution 2 h before being sacrificed. Paraffin sections 
were incubated with primary antibodies (Supplementary Table S2) O/N at 4ºC. To detect BrdU, 
the paraffin sections were pre-incubated with heated 2N HCl for 15 min following by incubation 
in 0.1 M sodium borate [pH 8.5] during 10 min. The second day, sections were incubated with 
the appropriate secondary antibody. For IF, fluorescent antibodies (1:200 dilution) were used 
for 2h at room temperature. Prior to coverslip application, nuclei were counterstained with 
DAPI and imaging was done with Leica SP-5 confocal microscope. For IHC, sections were 
incubated with HRP conjugated antibodies (1:200 dilution) (Supplementary Table S2). Target 
proteins were detected with the ABC Kit and the DAB kit (Vector Laboratories).  
Western Blot analysis 
Protein extracts were prepared by re-suspending cell pellets or tumor tissue samples in lysis 
buffer (50 mM Tris (pH 7.5), 300 mM NaCl, 0.5% SDS, and 1% Triton X-100) and incubating 
the cells for 15 min at 100º. The lysed extracts were centrifuged at 13,000 g for 10 min at room 
temperature and the protein concentration was determined using a commercially available 
colorimetric assay (BCA Protein Assay Kit). Approximately 20 to 30 µg of protein were 
resolved by 10% or 12% SDS-PAGE and they were then transferred to a nitrocellulose 
membrane (Hybond-ECL, Amersham Biosciences). The membranes were blocked for 1 h at 
room temperature in TBS-T (10 mM Tris-HCl [pH 7.5], 100 mM NaCl, and 0.1% Tween-20) 
with 5% skimmed milk, and then incubated overnight at 4ºC with the corresponding primary 
antibody (Supplementary Table 2) diluted in TBS-T. Then, the membranes were incubated for 
2 h at room temperature with their corresponding secondary antibody (HRP-conjugated anti 
mouse or anti rabbit, DAKO) diluted in TBS-T. Proteins were visible by enhanced 
chemiluminiscence with ECL (Pierce) using Amersham imager 680 and the signal was 
quantified by Fiji-ImageJ software. 
Quantitative reverse-transcriptase PCR (qRT-PCR) 
RNA was extracted from the tissue or the cell pellets using RNA isolation Kit (Roche) and it 
was digested with DNase I (Roche) according to the manufacturer’s instructions. cDNA was 
synthesized with SuperScript II Reverse Transcriptase (Takara). qRT-PCR reactions were 
performed using the Light Cycler 1.5 (Roche) with the SYBR Premix Ex Taq (Takara). The 
primers used for each reaction are indicated in Supplementary Table S3. Gene expression was 
quantified by the double delta Ct method. 
 
  
Supplementary Table 1. List of GBM cell lines. The table indicates the genetic status of 
EGFR of the different primary GBM cell lines used in this study. (nd: not determined. 0: not 




























GBM1 Hospital 12 de Octubre 1 0 
GBM2 Hospital 12 de Octubre 0 0 
GBM3 Hospital 12 de Octubre 1 1 (EGFR vIII) 
GBM4 Hospital 12 de Octubre 1 1 (EGFR vIII) 
GBM5 Hospital 12 de Octubre 1 1 (EGFR vIII) 
GBM6 Hospital 12 de Octubre 1 1 (EGFR vIII) 
GBM7 Hospital 12 de Octubre 0 1 (V774M) 
GBM8 Hospital 12 de Octubre 0 1 
GBM9 Hospital 12 de Octubre nd nd 
GBM10 Hospital 12 de Octubre nd nd 
GBM11 Hospital 12 de Octubre nd nd 
GBM12 Hospital 12 de Octubre nd nd 
GBM13 Hospital 12 de Octubre nd nd 
GBM14 Hospital 12 de Octubre 0 0 
GBM15 Hospital 12 de Octubre nd nd 
GBM16 Hospital 12 de Octubre 1 0 
Supplementary Table S2. Antibodies used for western-blot (WB), immunohistochemistry 
(IHC), immunofluorescence (IF) and flow-cytometry (FC) analysis.  
 
Antibody Dilution Source 
α-SMA 1:500 (WB), 1:100 (IHC) Santa Cruz Biotechnology 
β-Actin 1:1000 (WB) Sigma 
BrdU 1:100 Dako 
AKT 1:1000 (WB) Cell Signaling 
CD248 1:500 (WB), 1:100 (IF) 
Santa Cruz Biotechnology, 
BDBiosciences 
CD34 1:100 (IF) Leica 
CD3-vg 1:20 (FC) Beckton Dickinson 
CD11b-647 1:40 (FC) Miltenyi 
CD45  1:100 (IHC) eBioscience 
CD45-488 1:40 (FC) Miltenyi 
CD49d-percy5 1:100(IF) BioLegend 
CD68- 488 1:100 (IF) BioRad 
EGFR 1:1000 (WB) Cell Signaling 
EGFR vIII 1:1000 (WB) Cell Signaling 
Endomucin 1:100 (IF) Santa Cruz Biotechnology 
GAPDH 1:500 (WB) Santa Cruz Biotechnology 
GFP 1:100 (IF) Santa Cruz Biotechnology 
HIF1α 1:500 (WB) Santa Cruz Biotechnology 
p-AKT 1:1000 (WB) Cell Signaling 
p-BMX 1:1000 (WB) Invitrogen 
p-EGFR 1:1000 (WB) Cell Signailing 
p-ERK 1:500 (WB) Santa Cruz Biotechnology 
p-SRC 1:1000 (WB) Cell Signaling 
p-STAT3 1:1000 (WB) Cell Signaling 
SOX9 1:1000(WB) Cell Signaling 
p-SOX9 1:1000 (WB) Abcam 
Cy3 anti- mouse 1:200 (IF) Jackson Immunoresearch 
Cy3 anti-rabbit 1:200 (IF) Jackson Immunoresearch 
Cy5 anti-mouse 1:200 (IF) Jackson Immunoresearch 
Cy5 anti-rabbit 1:200 (IF) Jackson Immunoresearch 
Cy5-anti rat 1:200 (IF) Jackson Immunoresearch 
HRP anti-mouse 1:5000 (WB), 1:1000(IHC) GE Healthcare 
HRP anti-rabbit 1:5000 (WB), 1:1000(IHC) Santa Cruz Biotechnology 
HRP anti-rabbit 1:5000 (WB), 1:1000(IHC) Cell Signaling 
 
  
Supplementary Table S3. Primers used for the qRT-PCR analysis. 
Species Gene  Forward (5'-3´) Reverse (5'-3´) 
mouse CD31 TCCAGGTGTGCGAAATGCT TGGCAGCTGATGCCTATGG 
  VE-CAD TTACTCAATCCACATACACATTTTCG GCATGATGCTGTACTTGGTCATC 
  CD248 TTGATGGCACCTGGACAGAGGA TCCAGGTGCAATCTCTGAGGCT 
  αSMA ACCATCGGCAATGAGCGTTTCC GCTGTTGTAGGTGGTCTCATGG 
  PDGFRB CCGGAACAAACACACCTTCT TATCCATGTAGCCACCGTCA 
  MMP9 GCAAGGGGCCGTGTCTGGAGATTC GCCCACGTCGTCCACCTGGTT 
  LMNA TTGCCTCAACTGCAATGACAA TCTCGATGTCGGTAAAACCCC 
  VEGFR1 TTTGGCAAATACAACCCTTCAGA GCAGAAGATACTGTCACCACC 
  VEGFR2 CATCACCGAGAACAAGAACAAAACT GATACCTAGCGCAAAGAGACACATT 
  TEK ACGGACCATGAAGATGCGTCAACA TCACATCTCCGAACAATCAGCCTGG 
  EPHA2 GCACAGGGAAAGGAAGTTGTT CATGTAGATAGGCATGTCGTCC 
  AQP1 AGGCTTCAATTACCCACTGGA GTGAGCACCGCTGATGTGA 
  VEGF A TGCCAAGTGGTCCCAGGCTGC CCTGCACAGCGCATCAGCGG 
  PDGF A GATACCTCGCCCATGTTCTG CAGGCTGGTGTCCAAAGAAT 
  PDGF B GGGCCCGGAGTCGGCATGAA AGCTCAGCCCCATCTTCATCTTACGG 
  PGF GAGGCCAGAAAGTCAGGGGGC ATGGGCCGACAGTAGCTGCGA 
  NG2 GACGGCGCACACACTTCTC TGTTGTGATGGGCTTGTCAT 
  End TGCACTTGGCCTACGACTC  TGGAGGTAAGGGATGGTAGCA 
  Pi3kca GCTCTTCGCCATCACACAAAC GGCATTCCTGTCATCAGCATC 
  Cxcr4 GACTGGCATAGTCGGCAATGGA CAAAGAGGAGGTCAGCCACTGA 
  Cx45 ACTCCCTCTGTGATGTACCTGG GTGCTGTTTCCAACGCATGGCA 
  Timp1 TCTTGGTTCCCTGGCGTACTCT GTGAGTGTCACTCTCCAGTTTGC 
  Chi3l1 GCTTTGCCAACATCAGCAGCGA AGGAGGGTCTTCAGGTTGGTGT 
  Lox CATCGGACTTCTTACCAAGCCG GGCATCAAGCAGGTCATAGTGG 
  Serpine1 CCTCTTCCACAAGTCTGATGGC GCAGTTCCACAACGTCATACTCG 
  Cav1 CACACCAAGGAGATTGACCTGG CCTTCCAGATGCCGTCGAAACT 
  Car9 GGCGAACGATTGAGGCTTCCTT GCTGGTGACAGCAAAGAGAAGG 
  Car12 TGGCTCTGAACACACCGTGAGT TTGTCACTGGCGGTGCTGAAGT 
  Atf3 GAAGATGAGAGGAAAAGGAGGCG GCTCAGCATTCACACTCTCCAG 
  Hmox1 CACTCTGGAGATGACACCTGAG GTGTTCCTCTGTCAGCATCACC 
human αSMA TAGCACCCAGCACCATGAAGATCA GAAGCATTTGCGGTGGACAATGGA 
  NG2 AGCTCTACTCTGGACGCC  ATCGACTGACAACGTGGC 
  CD248 AGACCACCACTCATTTGCCTGGAA AGTTGGGATAATGGGAAGCGTGGT 
  PDGFRB ACGGCTCTACATCTTTGTGCCAGA TCGGCATGGAATGGTGATCTCAGT 
  SERPINE CATAGTGGAAGTGATAGAT ACTCTGTTAATTCGTCTT 
  CD34 CCTCAGTGTCTACTGCTGGTCT GGAATAGCTCTGGTGGCTTGCA 
  VEGFA CTAACACTCAGCTCTGCCC  ACACACAAATACAAGTTGCCAA 
  ANGPT2 ATTCAGCGACGTGAGGATGGCA GCACATAGCGTTGCTGATTAGTC 
  IGFBP2 CGAGGGCACTTGTGAGAAGCG TGTTCATGGTGCTGTCCACGTG 
  CHI3L1 CCACAGTCCATAGAATCCTCGG TGCCTGTCCTTCAGGTACTGCA 
  LOX GATACGGCACTGGCTACTTCCA GCCAGACAGTTTTCCTCCGCC 
  CAV1 CCAAGGAGATCGACCTGGTCAA GCCGTCAAAACTGTGTGTCCCT 
  CAIX GTGCCTATGAGCAGTTGCTGTC AAGTAGCGGCTGAAGTCAGAGG 
  CAXII GACCTTTATCCTGACGCCAGCA CATAGGACGGATTGAAGGAGCC 
  ATF3 CGCTGGAATCAGTCACTGTCAG CTTGTTTCGGCACTTTGCAGCTG 
  HMOX CCAGGCAGAGAATGCTGAGTTC AAGACTGGGCTCTCCTTGTTGC 
  CD31 AAGTGGAGTCCAGCCGCATATC ATGGAGCAGGACAGGTTCAGTC 
  END GCAAGCACTTCAGCAACCAGCC GGATCTGCCTTCCAGCACATTC 
 SOX9 AGGAAGCTCGCGGACCAGTAC GGTGGTCCTTCTTGTGCTGCAC 
 
 
